Insulin Degrading Enzyme Variants and Alzheimer's Disease
Author Information
Author(s): Belbin Olivia, Crump Michael, Bisceglio Gina D., Carrasquillo Minerva M., Morgan Kevin, Younkin Steven G.
Primary Institution: Mayo Clinic College of Medicine
Hypothesis
Can insulin degrading enzyme (IDE) variants affect gene expression related to Alzheimer's disease?
Conclusion
Certain IDE variants are associated with altered gene expression and may influence the risk of Alzheimer's disease.
Supporting Evidence
- The IDE variant v311 is linked to increased IDE mRNA and decreased Alzheimer's disease risk.
- In vitro tests showed that certain IDE variants significantly altered reporter gene expression.
- The study suggests that multiple variants may collectively influence IDE expression.
Takeaway
Some changes in genes can help us understand Alzheimer's disease better, and certain gene variants might be good targets for treatment.
Methodology
The study involved cloning IDE variants into a vector and testing their effects on gene expression in cell lines.
Potential Biases
Potential confounding factors in the experimental design and analysis.
Limitations
The in vitro model may not fully reflect in vivo conditions, and the sample size may limit the power to detect subtle effects.
Participant Demographics
Human samples were used, but specific demographics are not provided.
Statistical Information
P-Value
0.006
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website